ClinicalTrials.gg
RecruitingNCT07723976Updated Nov 17, 2026

A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE

A Phase 3 interventional study of CBD-OS and Placebo in Developmental and Epileptic Encephalopathy (DEE), sponsored by Jazz Pharmaceuticals. Recruiting at 43 sites in 5 countries. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment

How we know

Updated Nov 17, 2026Now RecruitingFirst sites in 5 new countries+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
1 Year and older
Sex
All
01

Study summary

The efficacy, safety, and tolerability of CBD-OS have been evaluated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous sclerosis complex (TSC). The current JZP926-303 study is being conducted to evaluate the safety and efficacy of CBD-OS in participants with Developmental and Epileptic Encephalopathy (DEE).

Read the detailed description

This Phase 3, multicenter, randomized, placebo-controlled, double-blind study will evaluate the efficacy and safety of CBD-OS in participants aged ≥ 1 year with DEE. The primary objective of the 6-week Double-blind Treatment Period of the study is to assess the efficacy of CBD-OS in reducing the frequency of countable motor seizures compared with placebo in participants with DEE. In addition, the Double-Blind Treatment Period will also assess the safety and tolerability of CBD-OS. The optional 6-month open-label extension (OLE) will provide additional data on the long-term efficacy, safety, and tolerability of CBD-OS.

02

Conditions studied

  • Developmental and Epileptic Encephalopathy (DEE)

Keywords

  • Developmental and Epileptic Encephalopathy
  • JZP926-OS
  • CBD-OS
03

In context

Lead sponsor

Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.

Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participants are eligible to be included in the study only if all the following criteria apply:

  1. Is at least 1 year of age at the time of signing the /assent.
  2. Meets the clinical phenotype for DEE as specified in the protocol.
  3. Per the investigator, the underlying etiology contributes to developmental impairment and seizures.
  4. Has had, or is willing to complete, confirmatory imaging and/or genetic testing to determine etiology of DEE.
  5. Is currently receiving antiseizure intervention, such as treatment with a stable regimen of at least 1 ASM or an established intervention for epilepsy (eg, ketogenic diet or neurostimulation).
  6. All medications or interventions for epilepsy have been stable for ≥ 28 days prior to starting the baseline period (Visit 2) with no planned changes to the regimen for the duration of the Double-blind Treatment Period.

Participants are excluded from the study if any of the following criteria apply:

  1. Has a concurrent, confirmed diagnosis of non-epileptic seizures or events that can confound the assessment of the efficacy measures, in the opinion of the investigator.
  2. The etiology of the participant's seizures is a progressive neurologic disease.
  3. Has known or suspected to cannabinoids or any of the of the study intervention, such as sesame oil.
  4. Has an active central nervous system (CNS) infection, demyelinating disease, degenerative neurologic disease, or any CNS disease deemed to be progressive during the study that may confound the interpretation of the study results (including encephalitis).
  5. Is currently being treated with Epidiolex or recently received treatment with Epidiolex within 28 days prior to screening.
  6. Has experienced a lack of efficacy and/or poor tolerability to an adequate treatment regimen of Epidiolex based on medical history and the clinical judgement of the investigator. Participants who discontinued treatment for reasons other than safety, tolerability, or lack of efficacy and previously received Epidiolex ≥ 28 days prior to starting the Baseline Period (Visit 2) may be eligible for the study after consultation with the medical monitor and/or sponsor representative.
  7. Has been taking felbamate for less than 12 months prior to screening. Participants who are stable on felbamate for ≥ 12 months are eligible for inclusion.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    CBD-OS

    Participants with DEE will be randomized to CBD-OS up to 10 mg/kg twice daily for a 6-week treatment period.

    Drug: CBD-OS

  • Placebo comparator
    Placebo

    Participants with DEE will be randomized to matching placebo for a 6-week treatment period.

    Drug: Placebo

  • Experimental
    Open-Label Extension: CBD-OS

    Participants with DEE who completed the double-blind phase of the study and enter the optional OLE will begin a 22-week open-label treatment period with CBD-OS up to 10 mg/kg twice daily following a 2-week Blinded Transition Period.

    Drug: CBD-OS

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Countable Motor Seizure Frequency Per 28 Days

    Time frame: Baseline up to 6 weeks of double-blind treatment period

Secondary outcomes

  1. Change in Total Seizure Frequency Per 28 Days

    Time frame: Baseline up to 6 weeks of double-blind treatment period

  2. Proportion of Participants Who Achieve ≥ 50% Reduction From Baseline in Countable Motor Seizure Frequency

    Time frame: Baseline up to 6 weeks of double-blind treatment period

  3. Caregiver Global Impression of Change (CaGI-C) Score

    Time frame: Week 6 of double-blind treatment period

  4. Change from Baseline in Caregiver Global Impression of Severity (CaGI-S) Score

    Time frame: Week 6 of double-blind treatment period

  5. Change From Baseline in Number of Countable Motor Seizure-free Days per 28 Days

    Time frame: Baseline up to 6 weeks of double-blind treatment period

  6. Clinical Global Impression of Change (CGI-C) Score

    Time frame: Week 6 of double-blind treatment period

  7. Change from Baseline in Clinical Global Impression of Severity (CGI-S) Score

    Time frame: Week 6 of double-blind treatment period

  8. Number of Participants Reporting Treatment-emergent Adverse Events

    Time frame: Baseline up to 6 weeks of double-blind treatment period

  9. Mean Plasma Concentration of CBD

    Time frame: Baseline up to 6 weeks of double-blind treatment period

  10. Mean Plasma Concentration of Metabolite 7-OH-CBD

    Time frame: Baseline up to 6 weeks of double-blind treatment period

  11. Mean Plasma Concentration of Metabolite 7-COOH-CBD

    Time frame: Baseline up to 6 weeks of double-blind treatment period

07

Study locations

2 of 43 sites recruiting
  • University Of Alabama Birmingham
    Birmingham, Alabama 35233, United States
    Not yet recruiting
  • Barrow Institute (ESC)
    Phoenix, Arizona 85013, United States
    Not yet recruiting
  • UC Irvine
    Orange, California 92868, United States
    Not yet recruiting
  • Sutter Health
    Sacramento, California 95816, United States
    Not yet recruiting
  • UC Davis Health Midtown Ambulatory Care Center
    Sacramento, California 95817, United States
    Not yet recruiting
  • Yale School Of Medicine (ESC)
    New Haven, Connecticut 06504, United States
    Not yet recruiting
  • (DEECRN) Children's National Hospital Friendship Heights; Children's National Medical Center
    Washington D.C., District of Columbia 20016, United States
    Not yet recruiting
  • Pediatric Epilepsy & Neurology Specialists (PENS)
    Tampa, Florida 33609, United States
    Not yet recruiting
  • Hawaii Pacific Neuroscience (HPN) Comprehensive Epilepsy Center
    Honolulu, Hawaii 96817, United States
    Recruiting
  • Sinai Hospital of Baltimore
    Baltimore, Maryland 21209, United States
    Not yet recruiting
  • Mid Atlantic Epilepsy And Sleep Center (ESC)
    Bethesda, Maryland 20817, United States
    Recruiting
  • Hackensack Meridian Neuroscience Institute At JFK University Medical Center
    Edison, New Jersey 08820, United States
    Not yet recruiting
  • Northwell Health Division Of Pediatric Neurology (ESC)
    Lake Success, New York 11042, United States
    Not yet recruiting
  • (DEECRN) Weill Cornell Medicine Pediatric Neurology
    New York, New York 10021, United States
    Not yet recruiting
  • Cincinnati Children's Hospital Medical Center (ESC)
    Cincinnati, Ohio 45229, United States
    Not yet recruiting
  • (DEECRN) The Children's Hospital Of Philadelphia (CHOP)
    Philadelphia, Pennsylvania 19104, United States
    Not yet recruiting
  • McGovern Medical School UT Physicianspediatric Neurology Texas Medical Center
    Houston, Texas 77030, United States
    Not yet recruiting
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
    Not yet recruiting
  • Queensland Children's Hospital
    Brisbane, 4101, Australia
    Not yet recruiting
  • Monash Health (Monash Children's)
    Clayton, 3168, Australia
    Not yet recruiting
  • Royal Brisbane and Women's Hospital
    Herston, 4029, Australia
    Not yet recruiting
  • Bayside (The Alfred)
    Melbourne, 3004, Australia
    Not yet recruiting
  • The Children's Hospital at Westmead
    Melbourne, 3004, Australia
    Not yet recruiting
  • Austin Health Hospital
    Melbourne, 3084, Australia
    Not yet recruiting
  • Sydney Children's Hospital
    Randwick, 2031, Australia
    Not yet recruiting
  • Semmelweis Egyetem Altalanos Orvostudomanyi Kar Gyermekgyogyaszati Klinika
    Budapest, 1083, Hungary
    Not yet recruiting
  • Flash Clinic
    Budapest, 1125, Hungary
    Not yet recruiting
  • (EpiCARE)Orszagos Idegtudomanyi Intezet (Oiti) (National Institute Of Neurosurgery (NICN) Juhasz Pal Epilepszia Kozpont
    Budapest, 1145, Hungary
    Not yet recruiting
  • (EpiCARE Center) IRCCS Istituto delle Scienze Neurologiche di Bologna
    Bolognia, 40138, Italy
    Not yet recruiting
  • Ospedale dei Bambini
    Brescia, 25123, Italy
    Not yet recruiting
  • Salesi Pediatric Hospital Aou Delle Marche Ancona
    Cagliari, 9124, Italy
    Not yet recruiting
  • (EpiCARE Center) Istituto Giannina Gaslini IRCCS
    Genova, 16147, Italy
    Not yet recruiting
  • (EpiCARE Center) ASST Santi Paolo E Carlo Ospedale San Paolo Polo Universitario Centro Regionale Per L Epilessia
    Milan, 20142, Italy
    Not yet recruiting
  • ASST Fatebenefratelli Sacco-Ospedale Dei Bambini Vittore Buzzi
    Milan, 20154, Italy
    Not yet recruiting
  • (EpiCARE Center) Ospedale Pediatrico Bambino Gesu - Ambulatorio di Neurologia dell Epilessia e Disturbi del Movimento
    Roma, 00165, Italy
    Not yet recruiting
  • (EpiCARE Center) Universita Cattolica Del Sacro Cuore Policlinico Universitario Agostino Gemelli
    Roma, 00168, Italy
    Not yet recruiting
  • (EpiCARE Center) Azienda Ospedaliera Universitaria Integrata Verona (Aoui) Ospedale Policlinico Giambattista Rossi Di Borgo Roma
    Verona, 37126, Italy
    Not yet recruiting
  • Hospital Infantil Nino Jesus de Madrid
    Madrid, 28009, Spain
    Not yet recruiting
  • Hospital Universitario Clinico San Carlos Madrid
    Madrid, 28040, Spain
    Not yet recruiting
  • Hospital Materno Infantil De Malaga
    Málaga, 29011, Spain
    Not yet recruiting
  • Clinica Universidad De Navarra Pamploma
    Navarra, 31008, Spain
    Not yet recruiting
  • Hospital Navarra
    Navarra, 31008, Spain
    Not yet recruiting
  • Centro De Neurologia Avanzada (CAN) Sevilla
    Seville, 41013, Spain
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with ICMJE requirements, Jazz Pharmaceuticals may provide qualified external researchers access to individual participant data (IPD) and clinical trial data that underlie the results of this trial upon request. Qualified researchers can submit a request on https://www.jazzpharma.com/science/clinical-trial-data-sharing/ as outlined. Jazz Pharmaceuticals reserves the right not to consider a request. For inquiries about Jazz's data sharing policy contact clinicaldatasharing@jazzpharma.com.

Data sharing details ↗ · www.jazzpharma.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Sep 2029, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2026
First posted
Jul 23, 2026
StartActual
Oct 30, 2026
Primary completionEst.
Sep 4, 2029
CompletionEst.
Sep 4, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
43 sites added — first sites in Australia, Hungary, Italy, Spain and United States
Show 43 added (18 United States, 9 Italy, 7 Australia, 6 Spain, 3 Hungary)
  • University Of Alabama Birmingham · Birmingham, United States
  • Barrow Institute (ESC) · Phoenix, United States
  • UC Irvine · Orange, United States
  • Sutter Health · Sacramento, United States
  • UC Davis Health Midtown Ambulatory Care Center · Sacramento, United States
  • Yale School Of Medicine (ESC) · New Haven, United States
  • (DEECRN) Children's National Hospital Friendship Heights; Children's National Medical Center · Washington D.C., United States
  • Pediatric Epilepsy & Neurology Specialists (PENS) · Tampa, United States
  • Hawaii Pacific Neuroscience (HPN) Comprehensive Epilepsy Center · Honolulu, United States
  • Sinai Hospital of Baltimore · Baltimore, United States
  • Mid Atlantic Epilepsy And Sleep Center (ESC) · Bethesda, United States
  • Hackensack Meridian Neuroscience Institute At JFK University Medical Center · Edison, United States
  • Northwell Health Division Of Pediatric Neurology (ESC) · Lake Success, United States
  • (DEECRN) Weill Cornell Medicine Pediatric Neurology · New York, United States
  • Cincinnati Children's Hospital Medical Center (ESC) · Cincinnati, United States
  • (DEECRN) The Children's Hospital Of Philadelphia (CHOP) · Philadelphia, United States
  • McGovern Medical School UT Physicianspediatric Neurology Texas Medical Center · Houston, United States
  • Seattle Children's Hospital · Seattle, United States
  • Queensland Children's Hospital · Brisbane, Australia
  • Monash Health (Monash Children's) · Clayton, Australia
  • Royal Brisbane and Women's Hospital · Herston, Australia
  • Bayside (The Alfred) · Melbourne, Australia
  • The Children's Hospital at Westmead · Melbourne, Australia
  • Austin Health Hospital · Melbourne, Australia
  • Sydney Children's Hospital · Randwick, Australia
  • Semmelweis Egyetem Altalanos Orvostudomanyi Kar Gyermekgyogyaszati Klinika · Budapest, Hungary
  • Flash Clinic · Budapest, Hungary
  • (EpiCARE)Orszagos Idegtudomanyi Intezet (Oiti) (National Institute Of Neurosurgery (NICN) Juhasz Pal Epilepszia Kozpont · Budapest, Hungary
  • (EpiCARE Center) IRCCS Istituto delle Scienze Neurologiche di Bologna · Bolognia, Italy
  • Ospedale dei Bambini · Brescia, Italy
  • …and 13 more on the registry record
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    43 sites added — first sites in Australia, Hungary, Italy, Spain and United States
    Show 43 added (18 United States, 9 Italy, 7 Australia, 6 Spain, 3 Hungary)
    • University Of Alabama Birmingham · Birmingham, United States
    • Barrow Institute (ESC) · Phoenix, United States
    • UC Irvine · Orange, United States
    • Sutter Health · Sacramento, United States
    • UC Davis Health Midtown Ambulatory Care Center · Sacramento, United States
    • Yale School Of Medicine (ESC) · New Haven, United States
    • (DEECRN) Children's National Hospital Friendship Heights; Children's National Medical Center · Washington D.C., United States
    • Pediatric Epilepsy & Neurology Specialists (PENS) · Tampa, United States
    • Hawaii Pacific Neuroscience (HPN) Comprehensive Epilepsy Center · Honolulu, United States
    • Sinai Hospital of Baltimore · Baltimore, United States
    • Mid Atlantic Epilepsy And Sleep Center (ESC) · Bethesda, United States
    • Hackensack Meridian Neuroscience Institute At JFK University Medical Center · Edison, United States
    • Northwell Health Division Of Pediatric Neurology (ESC) · Lake Success, United States
    • (DEECRN) Weill Cornell Medicine Pediatric Neurology · New York, United States
    • Cincinnati Children's Hospital Medical Center (ESC) · Cincinnati, United States
    • (DEECRN) The Children's Hospital Of Philadelphia (CHOP) · Philadelphia, United States
    • McGovern Medical School UT Physicianspediatric Neurology Texas Medical Center · Houston, United States
    • Seattle Children's Hospital · Seattle, United States
    • Queensland Children's Hospital · Brisbane, Australia
    • Monash Health (Monash Children's) · Clayton, Australia
    • Royal Brisbane and Women's Hospital · Herston, Australia
    • Bayside (The Alfred) · Melbourne, Australia
    • The Children's Hospital at Westmead · Melbourne, Australia
    • Austin Health Hospital · Melbourne, Australia
    • Sydney Children's Hospital · Randwick, Australia
    • Semmelweis Egyetem Altalanos Orvostudomanyi Kar Gyermekgyogyaszati Klinika · Budapest, Hungary
    • Flash Clinic · Budapest, Hungary
    • (EpiCARE)Orszagos Idegtudomanyi Intezet (Oiti) (National Institute Of Neurosurgery (NICN) Juhasz Pal Epilepszia Kozpont · Budapest, Hungary
    • (EpiCARE Center) IRCCS Istituto delle Scienze Neurologiche di Bologna · Bolognia, Italy
    • Ospedale dei Bambini · Brescia, Italy
    • …and 13 more on the registry record
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07723976
Collaborators
Jazz Pharmaceuticals Research UK Limited
Responsible party
Sponsor
First posted
Jul 23, 2026
Start date
Oct 30, 2026
Primary completion
Sep 4, 2029 (estimated)
Completion
Sep 4, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Clinical Trial Disclosure & Transparency
Contact
ClinicalTrialDisclosure@JazzPharma.com
215-832-3750

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion